Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis
Background: We performed a meta-analysis of the risk of hematological adverse events associated with ramucirumab. Methods: Eligible studies included randomized Phase II and III trials of patients with solid tumors on ramucirumab, describing events of anemia, leucopenia, neutropenia, febrile neutropenia and thrombocytopenia. Results: A total of 11 clinical trials were considered eligible for the meta-analysis. The relative risks of all-grade anemia, leucopenia, neutropenia, febrile neutropenia and thrombocytopenia were 0.88 (95% CI: 0.80-0.96; p = 0.007), 1.13 (95% CI: 0.85-1.49; p = 0.41), 1.25 (95% CI: 1.08-1.44; p = 0.002), 1.63 (95% CI: 1.30-2.06; p < 0.0001), 1.91 (95% CI: 1.52-2.42; p < 0.00001), respectively. Conclusion: Our meta-analysis has demonstrated an increased risk of febrile neutropenia, all-grade and high-grade neutropenia and thrombocytopenia with ramucirumab-based treatment compared with control..
| Medienart: |
Artikel |
|---|
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Future oncology - 11, 21, Seite 2949-2961 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdel-Rahman, Omar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.2217/fon.15.178 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC196167274X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC196167274X | ||
| 003 | DE-627 | ||
| 005 | 20230513051240.0 | ||
| 007 | tu | ||
| 008 | 160206nuuuuuuuuxx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon.15.178 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC196167274X | ||
| 035 | |a (DE-599)GBVOLC196167274X | ||
| 035 | |a (PRQ)f1362-b6c3f3afd829f6878e7847933475b3b7ad3bd77a0e4a7a7e02807dbe3606c7eb0 | ||
| 035 | |a (KEY)0579067000000000011002102949riskofhematologicaltoxicitiesinpatientswithsolidtu | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ZDB |
| 100 | 1 | |a Abdel-Rahman, Omar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Background: We performed a meta-analysis of the risk of hematological adverse events associated with ramucirumab. Methods: Eligible studies included randomized Phase II and III trials of patients with solid tumors on ramucirumab, describing events of anemia, leucopenia, neutropenia, febrile neutropenia and thrombocytopenia. Results: A total of 11 clinical trials were considered eligible for the meta-analysis. The relative risks of all-grade anemia, leucopenia, neutropenia, febrile neutropenia and thrombocytopenia were 0.88 (95% CI: 0.80-0.96; p = 0.007), 1.13 (95% CI: 0.85-1.49; p = 0.41), 1.25 (95% CI: 1.08-1.44; p = 0.002), 1.63 (95% CI: 1.30-2.06; p < 0.0001), 1.91 (95% CI: 1.52-2.42; p < 0.00001), respectively. Conclusion: Our meta-analysis has demonstrated an increased risk of febrile neutropenia, all-grade and high-grade neutropenia and thrombocytopenia with ramucirumab-based treatment compared with control. | ||
| 650 | 4 | |a neutropenia | |
| 650 | 4 | |a anemia | |
| 650 | 4 | |a thrombocytopenia | |
| 650 | 4 | |a ramucirumab | |
| 700 | 1 | |a ElHalawani, Hesham |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology |d London : Future Medicine Ltd, 2005 |g 11, 21, Seite 2949-2961 |w (DE-627)52756463X |w (DE-600)2274956-1 |w (DE-576)9527564638 |x 1479-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g number:21 |g pages:2949-2961 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.2217/fon.15.178 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 11 |e 21 |h 2949-2961 | ||